Start ELIGIBLE patients ON a 30-day
free trial of brand-name LEVOXYL*


Log in or call 1-866-295-7600 to request free trial vouchers. Terms and conditions apply.*

Help your patients start and stay on track with their treatment

  • With the offer available for download at LEVOXYL.com, eligible patients receive a free 1-month supply of brand-name LEVOXYL
  • After completing their 30-day free trial, many insured patients may pay less than $15 a month and as a result can continue to get brand-name LEVOXYL1†
  • LEVOXYL is available in 11 different dose strengths to help you meet the dosing needs of each individual patient2

Remember to indicate no substitution when prescribing
brand-name LEVOXYL by writing DAW, brand only, or medically necessary on LEVOXYL prescriptions

*Terms and conditions apply. Offer only accepted at participating pharmacies. Offer is not health insurance. No   membership fees. Average savings for all patients is approximately $15.

Out-of-pocket cost will vary based on coverage.

Important Safety Information

WARNING: Thyroid hormones, including LEVOXYL® (levothyroxine sodium), either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

LEVOXYL is contraindicated in patients with untreated subclinical or overt thyrotoxicosis of any etiology, acute myocardial infarction, or uncorrected adrenal insufficiency. LEVOXYL is contraindicated in patients with hypersensitivity to any of its inactive ingredients.

LEVOXYL should not be used in patients with nontoxic diffuse goiter or nodular thyroid disease if serum TSH level is already suppressed. If the TSH is not suppressed, LEVOXYL should be used with caution and monitoring for evidence of hyperthyroidism.

LEVOXYL should not be used for the treatment of male or female infertility unless this condition is associated with hypothyroidism.

LEVOXYL has a narrow therapeutic index. Careful dosage titration is necessary to avoid the consequences of over- or under-treatment such as effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and glucose and lipid metabolism.

Decreased bone mineral density (BMD) has been associated with long term LEVOXYL therapy in women. It is recommended that LEVOXYL be given in the minimum dose necessary to achieve the desired response.

LEVOXYL should be initiated at lower doses in the elderly and in patients with cardiovascular disorders.

Many drugs affect thyroid hormone pharmacokinetics and metabolism. Thyroid hormones also affect the pharmacokinetics and action of other drugs. The prescriber should be aware of this fact and should consult appropriate reference sources.

Acute massive overdosage of LEVOXYL may be a life-threatening emergency. Symptomatic and supportive therapy should be instituted immediately.

Adverse reactions associated with LEVOXYL are primarily those of hyperthyroidism due to therapeutic overdosage: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating, headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia, tremors, muscle weakness, palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest, dyspnea, diarrhea, vomiting, abdominal cramps, hair loss, flushing, menstrual irregularities, impaired fertility, and rarely seizures. Also in children: pseudo tumor cerebri, slipped capital femoral epiphysis; overtreatment may result in craniosyntosis, and premature closure of the epiphyses.

When LEVOXYL was not taken with water the following adverse events have been reported: choking, gagging, tablet stuck in throat and dysphagia.

Indications

LEVOXYL is indicated for hypothyroidism—as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism.

LEVOXYL is indicated for pituitary TSH suppression—in the treatment or prevention of various types of euthyroid goiters including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's thyroiditis) multinodular goiter and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Please see full Prescribing Information, including BOXED WARNING.

Terms and Conditions

By redeeming this free trial voucher, you acknowledge that you currently meet the eligibility criteria and comply with the terms and conditions described below:

  • You will receive a 30-day supply of LEVOXYL. Only 1 voucher per person may be redeemed under this program
  • Voucher must be presented to your pharmacist along with a valid prescription for LEVOXYL
  • Voucher good for one time only
  • The voucher will be accepted only at participating pharmacies
  • No membership fees
  • No claim for reimbursement for product dispensed pursuant to this voucher may be submitted to any third party payor. Federal and state health care program beneficiaries are not eligible for this voucher
  • This free trial voucher is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third party insurance, or where otherwise prohibited by law
  • This free trial voucher cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
  • This free trial is not health insurance
  • Offer good only in the U.S. and Puerto Rico
  • Only new patients may use this voucher. By redeeming this voucher, you certify that you are not currently using LEVOXYL. This voucher is not transferable
  • Pfizer reserves the right to rescind, revoke, or amend this free trial voucher without notice
  • This free trial voucher expires 12/31/15
  • Patients must be 18 or older
  • For questions regarding reimbursement, please call 1-800-422-5604, or write: Pfizer, ATTN: LEVOXYL, PO Box 2246, Morrisville, PA 19067-8025

References: 1. Data on file. [LEVOXYL. Fingertip Formulary LLC. www.fingertipformulary.com. Average co-pay includes patients with insurance coverage. September 1, 2013.] Pfizer Inc, New York, NY. 2. LEVOXYL® [package insert]. King Pharmaceuticals, Inc., Bristol, TN; 2008.

Please scroll for Important Safety Information and Indications

Important Safety Information

WARNING: Thyroid hormones, including LEVOXYL® (levothyroxine sodium), either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

LEVOXYL is contraindicated in patients with untreated subclinical or overt thyrotoxicosis of any etiology, acute myocardial infarction, or uncorrected adrenal insufficiency. LEVOXYL is contraindicated in patients with hypersensitivity to any of its inactive ingredients.

LEVOXYL should not be used in patients with nontoxic diffuse goiter or nodular thyroid disease if serum TSH level is already suppressed. If the TSH is not suppressed, LEVOXYL should be used with caution and monitoring for evidence of hyperthyroidism.

LEVOXYL should not be used for the treatment of male or female infertility unless this condition is associated with hypothyroidism.

LEVOXYL has a narrow therapeutic index. Careful dosage titration is necessary to avoid the consequences of over- or under-treatment such as effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and glucose and lipid metabolism.

Decreased bone mineral density (BMD) has been associated with long term LEVOXYL therapy in women. It is recommended that LEVOXYL be given in the minimum dose necessary to achieve the desired response.

LEVOXYL should be initiated at lower doses in the elderly and in patients with cardiovascular disorders.

Many drugs affect thyroid hormone pharmacokinetics and metabolism. Thyroid hormones also affect the pharmacokinetics and action of other drugs. The prescriber should be aware of this fact and should consult appropriate reference sources.

Acute massive overdosage of LEVOXYL may be a life-threatening emergency. Symptomatic and supportive therapy should be instituted immediately.

Adverse reactions associated with LEVOXYL are primarily those of hyperthyroidism due to therapeutic overdosage: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating, headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia, tremors, muscle weakness, palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest, dyspnea, diarrhea, vomiting, abdominal cramps, hair loss, flushing, menstrual irregularities, impaired fertility, and rarely seizures. Also in children: pseudo tumor cerebri, slipped capital femoral epiphysis; overtreatment may result in craniosyntosis, and premature closure of the epiphyses.

When LEVOXYL was not taken with water the following adverse events have been reported: choking, gagging, tablet stuck in throat and dysphagia.

Indications

LEVOXYL is indicated for hypothyroidism—as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism.

LEVOXYL is indicated for pituitary TSH suppression—in the treatment or prevention of various types of euthyroid goiters including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's thyroiditis) multinodular goiter and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Please see full Prescribing Information, including BOXED WARNING.